Please login to the form below

Not currently logged in
Email:
Password:

Gaucher disease

This page shows the latest Gaucher disease news and features for those working in and with pharma, biotech and healthcare.

Latest news

  • FDA changes its mind on 23andMe's genetic testing kits FDA changes its mind on 23andMe's genetic testing kits

    Along with Alzheimer's and Parkinson's, the new Genetic Health Risk (GHR) test covers coeliac disease, alpha-1 antitrypsin deficiency, early onset primary dystonia, Factor XI deficiency, type 1 Gaucher ... tests. The exemption will not however include

  • Langland and CAHG take top prizes at Best of Health Awards Langland and CAHG take top prizes at Best of Health Awards

    Healthcare Professional - Direct Marketing &Promotional Communications Individual. 'Hard to see, but easy to find - Rare Disease Awareness Campaign for Gaucher Disease' for Shire Pharmaceuticals, by bmore Creative .

  • Shire picks winner for Gaucher film contest Shire picks winner for Gaucher film contest

    A Shire spokesperson told PMLiVE: “We are hoping the videos are seen by the Gaucher community, and also by the general public, to raise awareness of Gaucher disease.”. ... At Shire, we are committed to working with the community to raise awareness of

  • Patient survey finds pharma falls short on drug pricing Patient survey finds pharma falls short on drug pricing

    PatientView highlights that the company ranked number one for corporate reputation - Sanofi - has a strong track record in developing innovative medicines for diseases with unmet needs, such as Gaucher disease and

  • Shire rumoured to be pursuing Actelion Shire rumoured to be pursuing Actelion

    Last month, Alexion unveiled an $8.4bn agreement to buy rare disease specialist Synageva, while Shire itself agreed to buy NPS for $5.2bn earlier this year. ... Buying Actelion would give Shire a portfolio of drugs to treat pulmonary artery hypertension

More from news
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics